S1389
Interdisciplinary - Health economics & health services research
ESTRO 2026
Digital Poster Highlight 1256
travel times greater than 60 minutes. For patients in Lecce, 26 pts (81.3%) fell within the 0–30 minute range, while six patients (18.7%) fell between 30 and 60 minutes. No patients reported travel times exceeding one hour. Patients with lower educational levels, reduced income, or living alone were more likely to report higher financial distress. Transportation, accommodation, and caregiver support emerged as major contributors to FT. Variables such as cancer stage, treatment duration, employment status, and family support significantly influenced the severity of financial distress. Patients with higher FT scores also reported lower overall quality of life, increased psychological burden, and reduced adherence to follow-up protocols.
Geographical and socio-economic disparities in the rising use of proton therapy for pediatric patients in France Boris SCHWARTZ 1 , Claire ALAPETITE 2 , Jordan BOUTER 3 , Emmanuel JOUGLAR 2 , Médéa LOCQUET 1 , Valentine MARTIN 8 , Véronique MINARD 6 , Fernand MISSOHOU 3 , Diana MITREA 9 , Jeanne RIVERAIN 3 , Camilla SATRAGNO 8 , Noura SELLAMI 8 , Nicolas SIMON 5,10 , Juliette THARIAT 3,11 , Lucie VIGNON 5,10 , Claire POULALHON 5,10 , Neige JOURNY 1 1 Center for Research in Epidemiology and Population Health – Unit 1018, EpiRad (Radiation Epidemiology team), Paris-Saclay University, Gustave Roussy, Inserm, Villejuif, France. 2 Department of Radiation Oncology, Proton Therapy Center, Institut Curie, Paris, France. 3 Department of Radiation Oncology, Centre François Line CLAUDE 4 , Emmanuel DESANDES 5 , Brice FRESNEAU 1,6 , William GEHIN 7 , Sylvie HELFRE 2 , Baclesse, Caen, France. 4 Department of Radiation Oncology, Centre Léon Bérard, Lyon, France. 5 Registre National des Cancers de l’Enfant (RNCE), Groupe Hospitalier Universitaire Paris-Sud, Assistance Publique Hôpitaux de Paris (AP-HP) / Institut de Cancérologie de Lorraine, Paris, France. 6 Children and Adolescent Oncology Department, Paris-Saclay University, Gustave Roussy, Villejuif, France. 7 Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France. 8 Department of Radiation Oncology, Université Paris-Saclay, Gustave Roussy, Villejuif, France. 9 Department of Radiation Oncology, University of Côte d’Azur, Nice, France. 10 Center for Research in Epidemiology and StatisticS (CRESS), Obstetrical Perinatal and Pediatric Life course Epidemiology (OPPaLE) team, Université Paris-Cité, Université Sorbonne Paris Nord, INSERM, INRAe, Paris, France. 11 ENSICAEN, CNRS/IN2P3, LPC Caen UMR6534, Université de Caen Normandie, Caen, France Purpose/Objective: In France, 800 children and adolescents are treated with radiotherapy each year. Currently, three proton beam therapy (PBT) facilities are operating. This study estimated the proportion of pediatric neoplasms treated with external beam radiotherapy (EBRT) who received PBT. We investigated clinical, socio-economic and geographical factors associated with the use of PBT, and temporal trends of the associations. Material/Methods: Using data from the national childhood cancer registry, we included all individuals diagnosed with a neoplasm before the age of 18 years between 2006 and 2021 in France who were primary or secondary treated with EBRT (excluding total body irradiation). We evaluated the proportion of them who were
Conclusion: FT is a complex interplay of clinical, psychological, and social factors. It influences treatment decisions, adherence, and overall patient well-being. Systematic screening for FT and early identification allows for timely support. The oncological staff must be trained to recognize signs of FT and provide personalized guidance, as informing patients about available financial aid, transportation services and social support networks. The study lays the groundwork for further research into FT and supports the development of standardized tools and protocols for managing financial distress in clinical practice. References: 1. Mitchell AP: We Should Treat Financial Toxicity With Curative, Rather Than Palliative, Intent. JCO Oncol Pract 18:95-96, 20222. Giap F, Chino F. : Systems-Level Changes to Address Financial Toxicity in Cancer Care. JCO Oncol Pract 18:310-311, 20223. Fabian A. et al: Financial toxicity in cancer patients treated with radiotherapy in Germany-a cross-sectional study. Strahlenther Onkol 198:1053-1061, 20224. Riva S. et al: Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. BMJ Open 11:e049128, 2021 Keywords: Financial and Management Toxicity
Made with FlippingBook - Share PDF online